These top ASX 200 stocks could rise 25% to 60%

If you are looking for quality ASX 200 stocks to buy for big potential returns, then read on!

Listed below are three shares that analysts believe can rise very strongly from where they trade today.

After which, they have the potential to compound and build wealth for investors long into the future. Here’s why they could be top picks right now:

Cochlear Ltd (ASX: COH)

The first ASX 200 stock that could be a top buy is hearing implant leader Cochlear. It appears well position for growth over the long term thanks to rising demand for its devices on the back of ageing populations across the globe and broader access to hearing healthcare.

And with a robust balance sheet and a track record of delivering both earnings and dividend growth, Cochlear could be a blue chip to buy and hold onto for the next decade.

UBS currently rates Cochlear as a buy with a $350.00 price target. This implies potential upside of 25% for investors over the next 12 months.

ResMed Inc. (ASX: RMD)

Another ASX 200 stock to buy and hold could be ResMed. With more than one billion people worldwide estimated to suffer from sleep apnoea, and the vast majority undiagnosed, ResMed has a significant growth runway over the next decade and beyond. The company continues to innovate across masks, devices and software while benefiting from rising awareness and diagnosis rates. Its cloud-connected ecosystem creates sticky customer relationships and high recurring revenue. For investors seeking a defensive growth story backed by secular demand, ResMed could be a top pick.

Macquarie has an outperform rating and $49.20 price target on its shares. This suggests that upside of 25% is possible for investors from current levels.

Xero Ltd (ASX: XRO)

A third ASX 200 stock to consider buying and holding is Xero. It is one of the world’s leading cloud accounting platforms and still has a huge global market to chase. With more than 4.5 million subscribers and NZ$2.7 billion in annualised monthly recurring revenue, the company remains in the early stages of penetrating a total addressable market estimated at around 100 million small businesses. As digital adoption accelerates in the UK, North America and Asia, Xero’s subscription model and high customer lifetime value create a powerful long-term growth engine.

Ord Minnett is bullish on Xero’s outlook. It recently put a buy rating and $200.00 price target on its shares. This implies potential upside of 60% for investors between now and this time next year.

The post These top ASX 200 stocks could rise 25% to 60% appeared first on The Motley Fool Australia.

More reading

• Macquarie reveals ASX 200 share tips in each market sector for 2026
• It’s time to buy: 1 Australian stock that hasn’t been this cheap in years
• Want to build wealth? Here’s how Warren Buffett does it
• Two ASX tech stocks Wilsons Advisory says are a buy after the recent tech sell-off
• 2 top ASX shares I’d buy with $2,000 right now

Motley Fool contributor James Mickleboro has positions in Cochlear, ResMed, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Macquarie Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended Macquarie Group, ResMed, and Xero. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.